Other inhibitors, such as CCG-1423 (MRTF-A) [112], epoxomicin (proteasome) [113], erlotinib [114], baicalein [114], and sorafenib [22], also suppress EMT by modulating TGF-β signaling, highlighting their therapeutic potential for AMD. The gene discussed is TGFB1; the disease is age-related macular degeneration.